NCT06773208View on ClinicalTrials.gov

A Study of Azacitidine and Venetoclax in People With Acute Myeloid Leukemia (AML)

PHASE2RecruitingINTERVENTIONAL
Enrollment

30

Participants

Timeline

Start Date

January 7, 2025

Primary Completion Date

January 31, 2027

Study Completion Date

January 31, 2027

Conditions
Acute Myeloid Leukemia (AML)
Interventions
DRUG

Azacitidine (AZC)

75 mg/m2 daily, on days 1-7, given IV or SC

DRUG

Venetoclax

Venetoclax 400 mg orally daily on days 1-28

Trial Locations (7)

10065

RECRUITING

Memorial Sloan Kettering Cancer Center (All Protocol Activities), New York

10604

RECRUITING

Memorial Sloan Kettering Westchester (Limited Protocol Activities), Harrison

11553

RECRUITING

Memorial Sloan Kettering Nassau (All Protocol Activities), Rockville Centre

11725

RECRUITING

Memorial Sloan Kettering Suffolk-Commack (All Protocol Activities), Commack

07920

RECRUITING

Memorial Sloan Kettering at Basking Ridge (All Protocol Activities), Basking Ridge

07748

RECRUITING

Memorial Sloan Kettering Monmouth (All Protocol Activities), Middletown

07645

RECRUITING

Memorial Sloan Kettering Bergen (All Protocol Activities), Montvale

All Listed Sponsors
lead

Memorial Sloan Kettering Cancer Center

OTHER